Inga Ellzey urges dermatology practices to conduct mid-year revenue cycle review

Billing consultancy Inga Ellzey is advising dermatology practices to perform a mid-year review of their revenue cycle performance before year-end closes. The firm highlights common leaks in derm billing, including improper use of modifier 25 with E/M services, incorrect coding for surgical procedures with biopsies, and denials for phototherapy and biologic drug administration. With payer policy updates and potential Medicare cuts on the horizon, the recommendation is to run key performance indicator reports now for A/R days, denial rates by payer and by reason, and clean claim rates. Identify your top three denial drivers and implement a corrective workflow by October to protect Q4 collections.